| 대한안과학회 학술대회 발표 연제 초록 |
| 망막 F-037 |
| 자성 산화철 나노입자 라벨링된 광수용체 전구세포의 자기공명영상을 이용한 추적관찰 |
1제주대학교 의과대학 안과학교실 2서울대학교병원 의생명연구원 망막변성연구소 3제일약품 4서울대학교 의과대학 안과학교실 |
| 마대중1,2, 임미선3, 박운철2,4, 박정범2, 지소연3, 유형곤2,4 |
목적 : In vivo cell tracking is a powerful tool for the optimization and monitoring of cell therapy. Magnetic resonance imaging (MRI) can be used to visualize transplanted cells labeled with superparamagnetic iron oxide nanoparticles (SPIONs), as well as the surrounding tissues. However, the applicability of these techniques in vivo in the retina has not been investigated. The goal of this study was to evaluate the feasibility of SPION labeling and MRI tracking of photoreceptor precursors transplanted into the subretinal space. 방법 : Photoreceptor precursors derived from human embryonic stem cells were labeled with SPIONs using the FeraTrack MRI contrast agent kit (Miltenyi Biotec Inc., Auburn, CA, USA). Royal College of Surgeons rats were classified into four experimental groups as follows: those injected with culture medium, unlabeled photoreceptor precursors, SPION-containing medium, and SPION-labeled photoreceptor precursors. All rats underwent subretinal injection by a transscleral approach and were examined by 9.4T MRI with T2*-weighted sequences (T2*WI) from 1 day to 12 weeks after transplantation. 결과 : Hypointense signals corresponding to the transplanted SPION-labeled photoreceptor precursors and SPION-containing medium were clearly visible at the injection site at 1 day after transplantation. The hypointense signal of the SPION-labeled photoreceptor precursors decreased but remained visible over the entire follow-up period. At 12 weeks after transplantation, histological analysis showed that transplanted SPION-labeled photoreceptor precursors were viable, and their distribution corresponded to the hypointense signal observed on T2*WI. 결론 : This study demonstrated that SPION labeling and MRI tracking of photoreceptor precursors transplanted into the subretinal space are feasible and can be utilized in cell therapy for degenerative retinal diseases. |